We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From May 2019 to May 2024
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Tuesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation for its investigational vaccine for the prevention of respiratory syncytial virus in adults at least 60 years of age.
Janssen said there are no preventive vaccines or effective antiviral treatments currently available for RSV, a highly-contagious, potentially life-threatening respiratory infection that affects more than 64 million people a year.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
Janssen said older adults are among those at highest risk of developing RSV. The company said its investigational vaccine is currently in a phase 2b proof-of-concept study in adults who are at least 65 years old.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 03, 2019 10:29 ET (14:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
